Two multinational drugmakers are teaming up with top global health groups to protect millions of girls in the world's poorest countries from deadly cervical cancer. Starting with pilot programs in eight Asian and African nations, the ambitious project ultimately is intended to inoculate more than 30 million girls in more than 40 countries by 2020.
Britain's competition watchdog has accused GlaxoSmithKline of paying off competitors to delay launches of their own versions of GSK's best-selling antidepressant, Seroxat. The Office of Fair Trading alleges GlaxoSmithKline concluded agreements which infringed competition law with Alpharma Limited, Generics (UK) Ltd and Norton Healthcare Ltd. over the supply of paroxetine, a cheaper version of Seroxat.
A panel of respiratory experts voted Wednesday in favor of approving an experimental inhaler drug from GlaxoSmithKline and Theravance for treating chronic lung disease. A majority of Food and Drug Administration panelists voted that the Breo Ellipta inhaler is safe and effective for long-term use...
Shares of Theravance and partner GlaxoSmithKline jumped today after the Food and Drug Administration posted its review of the companies' combination inhaler drug to treat lung disease. Glaxo and Theravance have asked the FDA to approve their experimental inhaler drug, Breo Ellipta, to treat complications of chronic lung disease.
The Food and Drug Administration will hold a meeting in June to reassess the safety of GlaxoSmithKline's former blockbuster drug Avandia, which was severely restricted in 2010 due to concerns about its impact on the heart. Regulators announced the highly unusual move in a government notice...
XenoPort Inc. said today that it has run into supply problems for its restless legs syndrome treatment Horizant. The company said it's received word from patients unable to fill their Horizant prescriptions. XenoPort hopes that a new stock of Horizant will be in pharmacies in June, but the timing is uncertain.
Eddingpharm a specialty pharmaceutical company based in China, has announced that the company has entered into a collaboration agreement with GSK, whereby Eddingpharm will acquire from GSK the exclusive right in mainland China to import, market, promote, distribute and sell Tykerb, a treatment for advanced or metastatic breast cancer that was recently approved by the SFDA.
BD (Becton, Dickinson and Company) today announced the appointment of Ellen Strahlman, M.D., M.H.Sc., to the newly created position of Chief Medical Officer and Senior Vice President, Research & Development, effective April 22, 2013. Dr. Strahlman will report to Chairman, CEO and President Vincent A. Forlenza and will serve as a member of the Company's Management Committee and Leadership Team.
More than two dozen of the world's largest pharmaceutical companies have agreed to provide funding and other support to Interpol's battle against counterfeit prescription drugs, the international police agency said Tuesday. Interpol's newly created Pharmaceutical Crime Program aims to help health...
Pharmaceutical giant GlaxoSmithKline PLC has donated a painting with a mysterious past to the Philadelphia Museum of Art. The work by N.C. Wyeth was one of 16 illustrations made in 1929 for George Herbert Palmer's translation of Homer's "The Odyssey." Wyeth sold the series to a private collector...
There's reassuring news for pregnant women miserable with morning sickness: A very large study in Denmark finds no evidence that using a popular anti-nausea drug will harm their babies. One in 10 pregnant women has nausea and vomiting bad enough to need medicine but many forgo it out of fear of side effects.
Kentucky's attorney general has joined in the flurry of legal action against GlaxoSmithKline, filing a lawsuit accusing the company of concealing the cardiovascular risks associated with a diabetes drug. The suit claims that GlaxoSmithKline LLC violated the state's Consumer Protection Act by overstating the effectiveness of the prescription drug Avandia and hiding its risks from consumers.
GSK and Theravance Announce FDA Acceptance of New Drug Application (NDA) Submission in the US for ANORO ELLIPTA(TM) for COPDFebruary 19, 2013 7:55 am | News | Comments
GlaxoSmithKline plc and Theravance, Inc. today announced that the New Drug Application (NDA) for the investigational once-daily LAMA/LABA combination medicine, UMEC/VI, for patients with chronic obstructive pulmonary disease (COPD), has been accepted by the U.S. Food and Drug Administration (FDA) indicating that the application is sufficiently complete to permit a substantive review.
The city's Navy Yard, a massive military powerhouse where battleships were born until the Cold War put it on ice, is celebrating a milestone that seemed a stretch when the Navy shipped out 17 years ago. Once the nation's first shipyard — its origins date to 1776 — the sprawling property is now home to 130 companies and 10,000 employees in industries as varied as fashion, pharmaceuticals, colleges and cupcakes.
GlaxoSmithKline is looking to cut costs further this year as it reported a sharp drop in fourth-quarter profit on the back of problems in Europe. The company says Wednesday it made a net profit of 839 million pounds ($1.31 billion) in the final three months of 2012, down nearly 35 percent on the previous year. Over the year it made a profit of 4.74 billion pounds against 2011's 5.46 billion pounds.
GlaxoSmithKline (GSK) and Biological E Limited (Biological E.), an Indian vaccines company, today announced an agreement to form a 50/50 joint venture (JV) for the early stage research and development of a six-in-one combination pediatric vaccine.
GlaxoSmithKline plc (LSE: GSK) today announced the appointment of Hans Wijers to its Board as a Non-Executive Director, effective 1st April 2013.
Regulatory update – GSK announces submission of albiglutide BLA to the US FDA for the treatment of type 2 diabetesJanuary 14, 2013 12:22 am | by GlaxoSmithKline | News | Comments
GlaxoSmithKline Enquiries: UK Media enquiries: David Mawdsley +44 (0) 20 8047 5502 (London) Sarah Spencer +44 (0) 20 8047 5502 (
GlaxoSmithKline plc (GSK) and Theravance, Inc. (NASDAQ: THRX) today announced the submission of a regulatory application in the European Union for the investigational once-daily LAMA/LABA combination medicine, UMEC/VI, for patients with chronic obstructive pulmonary disease (COPD).
Galapagos NV announced today that it successfully delivered a fifth pre-clinical candidate drug in its alliance with GlaxoSmithKline (GSK) triggering a milestone payment to Galapagos.
A potential treatment from Amicus Therapeutics and GlaxoSmithKline for Fabry disease, a rare disorder, missed its goals in late-stage testing, triggering a sell-off in Amicus' stock in after-hours trading.
GlaxoSmithKline plc (GSK) and Theravance, Inc. (NASDAQ: THRX) today announced the submission of a regulatory application in the US for the investigational once-daily LAMA/LABA combination medicine, UMEC/VI, for patients with chronic obstructive pulmonary disease (COPD).
GlaxoSmithKline and Amicus Therapeutics announce top-line six-month primary treatment period results from first Phase III Fabry monotherapy studyDecember 19, 2012 6:22 pm | by GlaxoSmithKline | News | Comments
GlaxoSmithKline plc (GSK) and Amicus Therapeutics (Nasdaq: FOLD) today announced the six-month primary treatment period results from the first Phase III global registration study (Study 011) of investigational oral migalastat HCl monotherapy in males and females with Fabry disease who had...
GlaxoSmithKline has announced that the FDA has approved FLUARIX QUADRIVALENT (Influenza Virus Vaccine) for the immunization of children (three years and older) and adults to help prevent disease caused by seasonal influenza (flu) virus subtypes A and type B contained in the vaccine.
GlaxoSmithKline plc [LSE/NYSE: GSK] announced today that the U.S. Food and Drug Administration (FDA) has approved raxibacumab for the treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs and for...